Cue Biopharma, Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax
Cue Biopharma, Inc. (CUE) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax of $1.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax · last filed 2025-11-12
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2025-09-30 was $1.00K.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2023-12-31 was $0.00.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2023-09-30 was $5.00K.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2023-06-30 was $34.00K.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2023 was $96.00K.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2022 was -$96.00K.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2021 was -$7.13K, a 140.86% decline from fiscal 2020.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2020 was $17.45K, a 2639.72% increase from fiscal 2019.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 12 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2025-09-30 | $1.00K 10-Q · filed 2025-11-12 | $1.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $5.00K derived: sum of 2 quarters · filed 2025-03-31 | $39.00K derived: sum of 3 quarters · filed 2025-03-31 | $96.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $5.00K 10-Q · filed 2024-11-14 | $39.00K derived: sum of 2 quarters · filed 2024-11-14 | $96.00K 10-Q · filed 2024-11-14 | $92.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $34.00K 10-Q · filed 2024-08-14 | $91.00K 10-Q · filed 2024-08-14 | $87.00K derived: sum of 3 quarters · filed 2024-08-14 | -$5.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $57.00K 10-Q · filed 2024-05-09 | $53.00K derived: sum of 2 quarters · filed 2024-05-09 | -$39.00K derived: sum of 3 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$96.00K derived: sum of 2 quarters · filed 2024-03-28 | -$96.00K 10-K · filed 2024-03-28 | -$95.87K 10-K · filed 2023-03-21 | |
| 2022-09-30 | -$92.00K 10-Q · filed 2023-11-03 | -$92.00K 10-Q · filed 2023-11-03 | |||
| 2021-12-31 | -$131.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | -$131.00 derived: sum of 2 quarters · filed 2023-03-21 | -$131.00 derived: sum of 3 quarters · filed 2023-03-21 | -$7.13K 10-K · filed 2023-03-21 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | -$7.00K 10-Q · filed 2022-11-14 | -$71.55K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$7.00K 10-Q · filed 2022-08-04 | -$71.55K derived: sum of 3 quarters · filed 2022-08-04 | -$154.55K derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$7.00K 10-Q · filed 2022-05-10 | -$71.55K derived: sum of 2 quarters · filed 2022-05-10 | -$154.55K derived: sum of 3 quarters · filed 2022-05-10 | -$248.55K derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$64.55K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | -$147.55K derived: sum of 2 quarters · filed 2022-03-16 | -$241.55K derived: sum of 3 quarters · filed 2022-03-16 | $17.45K 10-K · filed 2022-03-16 | |
| 2020-09-30 | -$83.00K 10-Q · filed 2021-11-09 | -$177.00K derived: sum of 2 quarters · filed 2021-11-09 | $82.00K 10-Q · filed 2021-11-09 | $71.64K derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | -$94.00K 10-Q · filed 2021-08-09 | $165.00K 10-Q · filed 2021-08-09 | $154.64K derived: sum of 3 quarters · filed 2021-08-09 | $154.64K derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $259.00K 10-Q · filed 2021-05-10 | $248.64K derived: sum of 2 quarters · filed 2021-05-10 | $248.64K derived: sum of 3 quarters · filed 2021-05-10 | $251.64K derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$10.36K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$10.36K derived: sum of 2 quarters · filed 2021-03-09 | -$7.36K derived: sum of 3 quarters · filed 2021-03-09 | $637.00 10-K · filed 2021-03-09 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $3.00K derived: sum of 2 quarters · filed 2020-11-09 | $11.00K 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $3.00K 10-Q · filed 2020-08-07 | $11.00K 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |